Immatics Appoints New CFO to Drive PRAME Therapy Commercialization

Immatics ( (IMTX) ) has shared an announcement.

On October 1, 2025, Immatics N.V. announced the appointment of Venkat Ramanan as its new Chief Financial Officer. Dr. Ramanan, a seasoned financial leader with over 25 years of experience in the biopharmaceutical industry, will succeed Arnd Christ. His extensive experience is expected to be instrumental in advancing Immatics’ PRAME franchise and moving its PRAME cell therapy, anzu-cel, toward commercialization. This strategic appointment is seen as a pivotal move as the company prepares for its first commercial launch and aims to strengthen its position as a leader in precision targeting of PRAME.

The most recent analyst rating on (IMTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.

Spark’s Take on IMTX Stock

According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.

Immatics’ overall stock score is primarily influenced by its financial performance and valuation challenges. The company faces significant profitability and cash flow issues, reflected in a low financial performance score. Technical analysis provides mixed signals, with no strong momentum in either direction. The negative P/E ratio highlights valuation concerns, further impacting the overall score.

To see Spark’s full report on IMTX stock, click here.

More about Immatics

Immatics N.V. is a clinical-stage biopharmaceutical company specializing in precision targeting of PRAME, a target expressed in over 50 types of cancer. The company is known for its cutting-edge science and robust clinical pipeline, which includes TCR T-cell therapies and TCR bispecifics, forming the broadest PRAME franchise with the most indications and modalities.

Average Trading Volume: 643,672

Technical Sentiment Signal: Buy

Current Market Cap: $961.5M

For a thorough assessment of IMTX stock, go to TipRanks’ Stock Analysis page.